BPC-157: what the rodent literature actually shows, and what it does not

BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable.

I would like to know what people here actually do about BPC-157, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.

Mine is below, with the reasoning, including the parts I am not confident about.

The version of BPC-157 that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.

The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.

Confirming post #16 from a second method, which matters more than confirming it from a second person.

The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.

The strength of my opinion here exceeds the strength of my evidence.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

That holds for the case as described. Change the assumptions and it may not.

Post #30 is right about the mechanism and I think understates the practical bit.

Adding a small correction to the BPC-157 summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.